Background: Numerous biologics (Bx) now exist to treat T2 diseases (Severe Asthma (SA), Chronic Rhinosinusitis with Nasal Polyposis (CRSwCRSwNP), Atopic Dermatitis (AD)), and Chronic Spontaneous Urticaria (CSU). Objective: To identify patients treated with Bx from a dynamic dispensing database using an algorithm-based methodology. Methods: We used the LRx database (Lifelink Treatment dynamics, IQVIA) covering 45% of the French Retails pharmacies. Patients with at least one Bx dispensing from April 2021 to March 2022 were included. An algorithm was designed to determine the indication of the Bx prescription analyzing all previous drug dispensing since March 2012 following a 3-steps procedure. Results: During the study period, 21,677 patients received at least one Bx. The algorithm identified 91.7% (n=19,884) patients with either CSU or a T2 disease (AD= 18.4%, CRSwNP= 1.5%, SA= 59.5%, and CSU= 12.4%). One percent had an association of diseases or an undetermined one (7.3%). SA was the main reason for Bx initiation (52%), followed by AD (29%), CSU (14%) and CRSwNP (5%). For SA patients with renewed biologic, omalizumab was the most frequently retrieved (48%) followed by benralizumab and mepolizumab (22% each), then dupilumab (8%). Dupilumab and omalizumab were the only initiated or renewed drug for CRSwNP and CSU, respectively. Dupilumab was mostly prescribed for AD patients (89% for patient-initiated vs 96% for patient-renewed). Conclusion: The algorithm was able to identify patients with T2 diseases or CSU under Bx treatments. This tool may help to follow the evolution of prescription patterns in the future.